{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:37:52Z","timestamp":1786995472633,"version":"build-2736575974"},"reference-count":116,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgpath.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Pathology Clinics"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.path.2024.10.002","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T21:16:47Z","timestamp":1731705407000},"page":"175-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tissue-Based Biomarkers Important for Prognostication and Management of Genitourinary Tumors, Including Surrogate Markers of Genomic Alterations"],"prefix":"10.1016","volume":"18","author":[{"given":"Leonie","family":"Beauchamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreeya","family":"Indulkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Erak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Salimian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0990-1115","authenticated-orcid":false,"given":"Andres","family":"Matoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.path.2024.10.002_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.humpath.2022.08.006","article-title":"The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges","volume":"136","author":"Mohanty","year":"2023","journal-title":"Hum Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.21037\/tau.2019.01.09","article-title":"Histological variants in non-muscle invasive bladder cancer","volume":"8","author":"Baumeister","year":"2019","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.path.2024.10.002_bib3","doi-asserted-by":"crossref","first-page":"275 e271","DOI":"10.1016\/j.urolonc.2022.02.004","article-title":"Histological variants of non-muscle invasive bladder cancer: survival outcomes of radical cystectomy vs. bladder preservation therapy","volume":"40","author":"Dursun","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib4","first-page":"701","article-title":"T1 substaging of nonmuscle invasive bladder cancer is associated with bacillus calmette-guerin failure and improves patient stratification at diagnosis","volume":"205","author":"de Jong","year":"2021","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.path.2024.10.002_bib5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/PAP.0000000000000309","article-title":"The genitourinary pathology society update on classification of variant histologies, t1 substaging, molecular taxonomy, and immunotherapy and PD-L1 testing implications of urothelial cancers","volume":"28","author":"Comperat","year":"2021","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00345-019-02782-y","article-title":"Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumor","volume":"38","author":"Hassan","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.path.2024.10.002_bib7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2217\/fon-2021-0841","article-title":"Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis","volume":"18","author":"Rizzo","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib8","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00262-022-03349-4","article-title":"Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis","volume":"72","author":"Santoni","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.path.2024.10.002_bib9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/14712598.2023.2201371","article-title":"Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward","volume":"23","author":"Bile-Silva","year":"2023","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.path.2024.10.002_bib10","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib11","doi-asserted-by":"crossref","first-page":"101925","DOI":"10.1016\/j.ctrv.2019.101925","article-title":"The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma","volume":"82","author":"Powles","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.path.2024.10.002_bib12","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.path.2024.10.002_bib13","first-page":"121","article-title":"Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer","volume":"3","author":"Lei","year":"2023","journal-title":"J\u00a0Natl Cancer Cent"},{"key":"10.1016\/j.path.2024.10.002_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 expression status in diverse cancers: review of results from 37,992 patients","volume":"34","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.path.2024.10.002_bib15","doi-asserted-by":"crossref","first-page":"100424","DOI":"10.1016\/j.modpat.2024.100424","article-title":"Characterizing the genomic landscape of the micropapillary subtype of urothelial carcinoma of the bladder harboring activating extracellular mutations of ERBB2","volume":"37","author":"Posada","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib16","doi-asserted-by":"crossref","first-page":"508 e501","DOI":"10.1016\/j.clgc.2023.04.002","article-title":"Clinicopathologic analysis of micropapillary urothelial carcinoma of the upper urinary tract: implications for HER2-targeted therapy","volume":"21","author":"Chou","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.path.2024.10.002_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00428-010-0952-2","article-title":"HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing","volume":"457","author":"Ruschoff","year":"2010","journal-title":"Virchows Arch"},{"key":"10.1016\/j.path.2024.10.002_bib19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ctrv.2014.11.003","article-title":"Emerging therapeutic targets in bladder cancer","volume":"41","author":"Carneiro","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.path.2024.10.002_bib20","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib21","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a Phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.path.2024.10.002_bib23","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2023.05.023","article-title":"Identification of lineage-specific transcriptional factor-defined molecular subtypes in small cell bladder cancer","volume":"85","author":"Feng","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.path.2024.10.002_bib24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.eururo.2021.10.009","article-title":"A\u00a0molecular inquiry into the role of antibody-drug conjugates in bacillus calmette-guerin-exposed non-muscle-invasive bladder cancer","volume":"81","author":"Choi","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.path.2024.10.002_bib25","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ajpath.2013.05.013","article-title":"Toward a molecular pathologic classification of urothelial carcinoma","volume":"183","author":"Sjodahl","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.path.2024.10.002_bib27","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A\u00a0consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.path.2024.10.002_bib28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00428-021-03145-y","article-title":"Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion","volume":"479","author":"Haghayeghi","year":"2021","journal-title":"Virchows Arch"},{"key":"10.1016\/j.path.2024.10.002_bib29","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/his.14883","article-title":"Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small-cell carcinoma of the bladder","volume":"82","author":"Parimi","year":"2023","journal-title":"Histopathology"},{"key":"10.1016\/j.path.2024.10.002_bib30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/PAI.0000000000000872","article-title":"Urothelial carcinoma in situ of the bladder: correlation of CK20 expression with adaptive immune resistance, response to BCG therapy, and clinical outcome","volume":"29","author":"Lombardo","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.path.2024.10.002_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11934-016-0576-4","article-title":"Grading of prostate cancer: past, present, and future","volume":"17","author":"Matoso","year":"2016","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.path.2024.10.002_bib32","doi-asserted-by":"crossref","first-page":"S477","DOI":"10.21037\/tau.2018.02.06","article-title":"Clinical significance of subtypes of Gleason pattern 4 prostate cancer","volume":"7","author":"Hassan","year":"2018","journal-title":"Transl Androl Urol"},{"issue":"Suppl 1","key":"10.1016\/j.path.2024.10.002_bib33","first-page":"S13","article-title":"The evolving landscape of prostate cancer somatic mutations","volume":"82","author":"Cotter","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.path.2024.10.002_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174291","article-title":"PTEN and DNA ploidy status by machine learning in prostate cancer","volume":"13","author":"Cyll","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.path.2024.10.002_bib35","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41467-022-30257-z","article-title":"MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets","volume":"13","author":"Qiu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.path.2024.10.002_bib36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.euo.2018.08.010","article-title":"Core biopsies from prostate cancer patients in active surveillance protocols harbor PTEN and MYC Alterations","volume":"2","author":"Gandellini","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib37","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1097\/PAS.0b013e31821e8761","article-title":"Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas","volume":"35","author":"Chaux","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib38","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1158\/1055-9965.EPI-12-0042","article-title":"The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis","volume":"21","author":"Pettersson","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.path.2024.10.002_bib39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.onc.1210640","article-title":"Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer","volume":"27","author":"Attard","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.path.2024.10.002_bib40","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41391-018-0093-2","article-title":"PTEN status assessment in the Johns Hopkins active surveillance cohort","volume":"22","author":"Tosoian","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.path.2024.10.002_bib41","doi-asserted-by":"crossref","first-page":"100147","DOI":"10.1016\/j.modpat.2023.100147","article-title":"ERG status at the margin is associated with biochemical recurrence after radical prostatectomy with positive surgical margins","volume":"36","author":"Salles","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib42","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.urolonc.2017.05.004","article-title":"Prognostic role of Ki-67 score in localized prostate cancer: a systematic review and meta-analysis","volume":"35","author":"Berlin","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib43","first-page":"e20223200","article-title":"Can we use Ki67 expression to predict prostate cancer aggressiveness?","volume":"49","author":"Maia","year":"2022","journal-title":"Rev Col Bras Cir"},{"key":"10.1016\/j.path.2024.10.002_bib44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/path.6057","article-title":"Automated Ki-67 labeling index assessment in prostate cancer using artificial intelligence and multiplex fluorescence immunohistochemistry","volume":"260","author":"Blessin","year":"2023","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib45","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2217\/bmm-2017-0322","article-title":"Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study","volume":"12","author":"Fantony","year":"2018","journal-title":"Biomarkers Med"},{"key":"10.1016\/j.path.2024.10.002_bib46","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/1055-9965.EPI-13-0696","article-title":"Tissue biomarkers for prognosis of prostate cancer: a systematic review and meta-analysis","volume":"23","author":"Zhao","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.path.2024.10.002_bib47","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S1470-2045(21)00522-2","article-title":"A\u00a0prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study","volume":"22","author":"Bancroft","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib48","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2012.44.1238","article-title":"Elevated risk of prostate cancer among men with Lynch syndrome","volume":"31","author":"Raymond","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib49","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.1158\/1078-0432.CCR-17-0955","article-title":"MSH2 loss in primary prostate cancer","volume":"23","author":"Guedes","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.path.2024.10.002_bib50","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.path.2024.10.002_bib51","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib52","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41391-021-00428-y","article-title":"Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative","volume":"25","author":"Vince","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.path.2024.10.002_bib53","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41391-019-0167-9","article-title":"Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance","volume":"23","author":"Herlemann","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.path.2024.10.002_bib54","first-page":"1216","article-title":"Risk factors for biopsy reclassification over time in men on active surveillance for early stage prostate cancer","volume":"204","author":"Lonergan","year":"2020","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.path.2024.10.002_bib55","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2217\/fon-2019-0745","article-title":"Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy","volume":"16","author":"Cimadamore","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib56","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.path.2024.10.002_bib57","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-20-4805","article-title":"Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms","volume":"27","author":"Tukachinsky","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.path.2024.10.002_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115522","article-title":"Circulating tumor DNA testing for homology recombination repair genes in prostate cancer: from the lab to the clinic","volume":"22","author":"Cimadamore","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.path.2024.10.002_bib59","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41379-021-00779-w","article-title":"New developments in existing WHO entities and evolving molecular concepts: the Genitourinary Pathology Society (GUPS) update on renal neoplasia","volume":"34","author":"Trpkov","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib60","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/PAS.0000000000001629","article-title":"Contemporary characterization and recategorization of adult unclassified renal cell carcinoma","volume":"45","author":"Kwon","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib61","doi-asserted-by":"crossref","first-page":"100472","DOI":"10.1016\/j.modpat.2024.100472","article-title":"High-grade, nonsarcomatoid chromophobe renal cell carcinoma: a series of 22 cases with novel molecular features on a subset","volume":"37","author":"Baraban","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib62","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1177\/10668969211003660","article-title":"ALK-rearranged Renal Cell Carcinoma (RCC): a Report of 2 cases and review of the literature emphasizing the distinction between VCL-ALK and non-VCL-ALK RCC","volume":"29","author":"Wangsiricharoen","year":"2021","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib63","doi-asserted-by":"crossref","first-page":"259 e251","DOI":"10.1016\/j.urolonc.2016.01.005","article-title":"Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy","volume":"34","author":"Nguyen","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib64","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.eururo.2011.06.041","article-title":"Prognostic factors and predictive models in renal cell carcinoma: a contemporary review","volume":"60","author":"Sun","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.path.2024.10.002_bib65","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1002\/cncr.33033","article-title":"Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial","volume":"126","author":"Motzer","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.path.2024.10.002_bib66","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.path.2024.10.002_bib67","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","article-title":"Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib68","article-title":"Biomarkers for immune checkpoint inhibitors in renal cell carcinoma","volume":"12","author":"Martin","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.path.2024.10.002_bib69","article-title":"Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma","volume":"8","author":"Labriola","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.path.2024.10.002_bib70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13073-020-00729-2","article-title":"Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival","volume":"12","author":"Wood","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.path.2024.10.002_bib71","article-title":"Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis","volume":"8","author":"Dizman","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.path.2024.10.002_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071945","article-title":"The Value of PD-L1 expression as predictive biomarker in metastatic renal cell carcinoma patients: a meta-analysis of randomized clinical trials","volume":"12","author":"Carretero-Gonzalez","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.path.2024.10.002_bib73","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41467-021-21068-9","article-title":"Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma","volume":"12","author":"Bakouny","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.path.2024.10.002_bib74","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.1016\/j.clgc.2019.03.018","article-title":"Metastatic chromophobe renal cell carcinoma: presence or absence of sarcomatoid differentiation determines clinical course and treatment outcomes","volume":"17","author":"Ged","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.path.2024.10.002_bib75","article-title":"Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"10","author":"Rini","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.path.2024.10.002_bib76","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00000478-200103000-00001","article-title":"Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases","volume":"25","author":"de Peralta-Venturina","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib77","doi-asserted-by":"crossref","first-page":"13979","DOI":"10.18632\/oncotarget.14704","article-title":"Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.path.2024.10.002_bib78","first-page":"860","article-title":"von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma","volume":"180","author":"Choueiri","year":"2008","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.path.2024.10.002_bib79","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von hippel-lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.path.2024.10.002_bib80","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ng.2699","article-title":"Integrated molecular analysis of clear-cell renal cell carcinoma","volume":"45","author":"Sato","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.path.2024.10.002_bib81","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/cncr.28521","article-title":"Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma","volume":"120","author":"Joseph","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.path.2024.10.002_bib82","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pena-Llopis","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.path.2024.10.002_bib83","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jamaoncol.2019.3158","article-title":"Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma","volume":"5","author":"Braun","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib84","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2022.04.021","article-title":"Impact of MET status on treatment outcomes in papillary renal cell carcinoma: a pooled analysis of historical data","volume":"170","author":"Albiges","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.path.2024.10.002_bib85","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaoncol.2020.2218","article-title":"Efficacy of Savolitinib vs Sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial","volume":"6","author":"Choueiri","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib86","first-page":"JCO2400767","article-title":"Final overall survival analysis of s1500: a randomized, phase II study comparing sunitinib with cabozantinib, crizotinib, and savolitinib in advanced papillary renal cell carcinoma","author":"Barata","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib87","doi-asserted-by":"crossref","DOI":"10.4132\/jptm.2024.07.31","article-title":"Histopathologic classification and immunohistochemical features of papillary renal neoplasm with potential therapeutic targets","author":"Park","year":"2024","journal-title":"J\u00a0Pathol Transl Med"},{"key":"10.1016\/j.path.2024.10.002_bib88","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/PAS.0000000000002117","article-title":"Positive GPNMB immunostaining differentiates renal cell carcinoma with fibromyomatous stroma associated with TSC1\/2\/MTOR alterations from others","volume":"47","author":"Li","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib89","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/path.5875","article-title":"GPNMB expression identifies TSC1\/2\/mTOR-associated and MiT family translocation-driven renal neoplasms","volume":"257","author":"Salles","year":"2022","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib90","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1097\/PAS.0000000000001940","article-title":"Xanthomatous giant cell renal cell carcinoma: another morphologic form of TSC -associated renal cell carcinoma","volume":"46","author":"Argani","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073995","article-title":"Activity of ALK inhibitors in renal cancer with ALK alterations: a systematic review","volume":"23","author":"Iannantuono","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.path.2024.10.002_bib92","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1038\/s41379-020-0578-0","article-title":"ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217","volume":"33","author":"Kuroda","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib93","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/his.14258","article-title":"The detection of isochromosome i(12p) in malignant germ cell tumours and tumours with somatic malignant transformation by the use of quantitative real-time polymerase chain reaction","volume":"78","author":"Fichtner","year":"2021","journal-title":"Histopathology"},{"key":"10.1016\/j.path.2024.10.002_bib94","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.humpath.2021.03.008","article-title":"Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing\/mate-pair sequencing","volume":"112","author":"Freitag","year":"2021","journal-title":"Hum Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib95","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/(SICI)1097-0142(19970501)79:9<1710::AID-CNCR11>3.0.CO;2-0","article-title":"MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis","volume":"79","author":"Albers","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.path.2024.10.002_bib96","first-page":"212","article-title":"Clinical impact of MDR1-expression in testicular germ cell cancer","volume":"29","author":"Schrader","year":"2007","journal-title":"Exp Oncol"},{"key":"10.1016\/j.path.2024.10.002_bib97","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/PAI.0b013e3181f05a66","article-title":"Immunohistochemistry expression of P53, Ki67, CD30, and CD117 and presence of clinical metastasis at diagnosis of testicular seminoma","volume":"19","author":"Gallegos","year":"2011","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.path.2024.10.002_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/life12020264","article-title":"Ki67 and LSD1 expression in testicular germ cell tumors is not associated with patient outcome: investigation using a digital pathology algorithm","volume":"12","author":"Lourenco","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.path.2024.10.002_bib99","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.18632\/oncotarget.27565","article-title":"Graded expression of microRNA-371a-3p in tumor tissues, contralateral testes, and in serum of patients with testicular germ cell tumor","volume":"11","author":"Belge","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.path.2024.10.002_bib100","first-page":"2709","article-title":"MicroRNAs in testicular cancer: implications for pathogenesis, diagnosis, prognosis and therapy","volume":"34","author":"Bezan","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.path.2024.10.002_bib101","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.urology.2016.07.037","article-title":"The evolving management of patients with clinical stage i seminoma","volume":"98","author":"Matulewicz","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.path.2024.10.002_bib102","first-page":"126","article-title":"Serum miRNA predicts viable disease after chemotherapy in patients with testicular nonseminoma germ cell tumor","volume":"200","author":"Leao","year":"2018","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.path.2024.10.002_bib103","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.eururo.2021.06.006","article-title":"Circulating MicroRNAs, the next-generation serum biomarkers in testicular germ cell tumours: a systematic review","volume":"80","author":"Leao","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.path.2024.10.002_bib104","doi-asserted-by":"crossref","first-page":"319","DOI":"10.5582\/irdr.2017.01070","article-title":"An up-date on epigenetic and molecular markers in testicular germ cell tumors","volume":"6","author":"Chieffi","year":"2017","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.path.2024.10.002_bib105","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1038\/s41379-021-00845-3","article-title":"Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features","volume":"34","author":"Rizzo","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib106","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.euf.2019.05.012","article-title":"Genomic features of metastatic testicular sex cord stromal tumors","volume":"5","author":"Necchi","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.path.2024.10.002_bib107","doi-asserted-by":"crossref","first-page":"E1197","DOI":"10.1210\/jc.2010-3031","article-title":"Mutation analysis of the LH receptor gene in Leydig cell adenoma and hyperplasia and functional and biochemical studies of activating mutations of the LH receptor gene","volume":"96","author":"Boot","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.path.2024.10.002_bib108","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.clgc.2021.02.002","article-title":"TERT gene fusions characterize a subset of metastatic leydig cell tumors","volume":"19","author":"Kruslin","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.path.2024.10.002_bib109","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/PAS.0000000000002022","article-title":"Inflammatory and nested testicular sex cord tumor: a novel neoplasm with aggressive clinical behavior and frequent EWSR1::ATF1 gene fusions","volume":"47","author":"Acosta","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib110","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/his.14225","article-title":"The Leydig cell tumour Scaled Score (LeSS): a method to distinguish benign from malignant cases, with additional correlation with MDM2 and CDK4 amplification","volume":"78","author":"Colecchia","year":"2021","journal-title":"Histopathology"},{"key":"10.1016\/j.path.2024.10.002_bib111","first-page":"415","article-title":"Clinical outcomes of local and metastatic testicular sex cord-stromal tumors","volume":"192","author":"Silberstein","year":"2014","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.path.2024.10.002_bib112","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.humpath.2019.09.013","article-title":"Morphology, p16, HPV, and outcomes in squamous cell carcinoma of the penis: a multi-institutional study","volume":"96","author":"Eich","year":"2020","journal-title":"Hum Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib113","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.humpath.2016.02.013","article-title":"Prevalence and distribution of 15 high-risk human papillomavirus types in squamous cell carcinoma of the scrotum","volume":"53","author":"Matoso","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib114","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/PAS.0000000000000192","article-title":"Squamous neoplasia of the scrotum: a series of 29 cases","volume":"38","author":"Matoso","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2024.06.013","article-title":"High-risk human papilloma virus status & outcomes for penile squamous cell carcinoma: a single institution experience","volume":"150","author":"Tekin","year":"2024","journal-title":"Hum Pathol"},{"key":"10.1016\/j.path.2024.10.002_bib116","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.21037\/tau.2019.08.37","article-title":"Inguinal lymph node dissection for penile cancer: a contemporary review","volume":"9","author":"Teh","year":"2020","journal-title":"Transl Androl Urol"}],"container-title":["Surgical Pathology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918124000795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918124000795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:30:55Z","timestamp":1760074255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875918124000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1875918124000795"],"URL":"https:\/\/doi.org\/10.1016\/j.path.2024.10.002","relation":{},"ISSN":["1875-9181"],"issn-type":[{"value":"1875-9181","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tissue-Based Biomarkers Important for Prognostication and Management of Genitourinary Tumors, Including Surrogate Markers of Genomic Alterations","name":"articletitle","label":"Article Title"},{"value":"Surgical Pathology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.path.2024.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}